What Edwards Lifesciences Corp's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 11 | 55 |
| Total trades | 22 | 159 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 105,657 | 646,812 |
| Disposed | 111,760 | 529,014 |
| Net activity | −6,103 | +117,797 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Dahl Andrew M. | SVP, Corporate Controller | Nov 13 | Withheld — tax / exercise cost · F | −101 | $105.80 | −$10.7K | 14,606 |
| Lippis Daniel J. | CVP, TAVR | Nov 10 | Disclosed 10b5-1 sale · S | −619 | $104.25 | −$64.5K | 40,034 |
| Lippis Daniel J. | CVP, TAVR | Nov 10 | Exercise / conversion · M | +619 | $72.68 | +$45K | 40,653 |
| Bobo Donald E Jr | CVP,Strategy/Corp Development | Nov 09 | Disclosed 10b5-1 sale · S | −48,900 | $103.05 | −$5.04M | 22,798 |
| Bobo Donald E Jr | CVP,Strategy/Corp Development | Nov 09 | Exercise / conversion · M | +48,900 | $72.68 | +$3.55M | 71,698 |
| Zovighian Bernard J | CEO | Nov 09 | Disclosed 10b5-1 sale · S | −13,916 | $102.78 | −$1.43M | 98,845 |
| Zovighian Bernard J | CEO | Nov 09 | Disclosed 10b5-1 sale · S | −9,184 | $103.39 | −$949K | 112,761 |
| Zovighian Bernard J | CEO | Nov 09 | Exercise / conversion · M | +23,100 | $72.68 | +$1.68M | 121,945 |
| Lippis Daniel J. | CVP, TAVR | Oct 08 | Disclosed 10b5-1 sale · S | −619 | $85.65 | −$53K | 40,034 |
| Lippis Daniel J. | CVP, TAVR | Oct 08 | Exercise / conversion · M | +619 | $72.68 | +$45K | 40,653 |
| Markowitz Wayne | CVP, JAPAC | Sep 14 | Withheld — tax / exercise cost · F | −568 | $84.37 | −$47.9K | 19,371 |
| Dahl Andrew M. | SVP, Corporate Controller | Sep 13 | Withheld — tax / exercise cost · F | −253 | $84.37 | −$21.3K | 14,615 |
| Markowitz Wayne | CVP, JAPAC | Sep 11 | Withheld — tax / exercise cost · F | −355 | $86.77 | −$30.8K | 19,939 |
| Lippis Daniel J. | CVP, TAVR | Sep 11 | Disclosed 10b5-1 sale · S | −619 | $87.51 | −$54.2K | 40,034 |
| Lippis Daniel J. | CVP, TAVR | Sep 11 | Exercise / conversion · M | +619 | $72.68 | +$45K | 40,653 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Sep 11 | Withheld — tax / exercise cost · F | −398 | $86.77 | −$34.5K | 43,926 |
| Dahl Andrew M. | SVP, Corporate Controller | Aug 31 | Open-market sale · S | −544 | $91.06 | −$49.5K | 14,868 |
| Bruls Annette | CVP, EMEACLA | Aug 28 | Open-market sale · S | −2,644 | $89.98 | −$238K | 17,984 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Aug 26 | Open-market sale · S | −30,646 | $90.99 | −$2.79M | 44,324 |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | Aug 26 | Open-market sale · S | −1,154 | $91.76 | −$106K | 74,970 |
Loading...